Wells Fargo
CLVS

Wells Fargo’s Clovis Oncology, Inc. CLVS Stock Holding History

Wells Fargo’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25,000
Closed -$315K – 6517
2015
Q4 		$315K Buy
+25,000
New +$1.61M ﹤0.01% 4181

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Wells Fargo's CLVS Position: Q4 2022 in Review

Wells Fargo sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 80,284 shares — an estimated $96K sold.

Wells Fargo first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $58.4M in Q3 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Wells Fargo reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Wells Fargo sold 80,284 Clovis Oncology, Inc. shares in Q4 2022, an estimated $96K.
  • Wells Fargo first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Wells Fargo's Clovis Oncology, Inc. position peaked at $58.4M in Q3 2015.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.